Syncromune

Syncromune is pioneering a first-in-class, in situ immunotherapy platform, SYNC-T, which combines partial oncolysis of a tumor with local infusion of a proprietary multi-target biologic drug. This approach aims to overcome the limitations of systemic immunotherapies by simultaneously addressing multiple immune suppression mechanisms while minimizing systemic toxicity. The company is advancing its lead candidate for mCRPC in the Phase 2 LEGION-100 trial and plans to expand into other metastatic solid tumors like non-small cell lung cancer and breast cancer. Founded in 2020, it is a private, pre-revenue company based in Boca Raton, Florida.

SYNC-T™, a personalized in situ (within the body) immunotherapy platform. It combines partial oncolysis of a tumor to release patient-specific antigens with direct intra-tumoral infusion of a proprietary multi-target biologic drug. This is designed to synchronize antigens, drug, and immune cells locally to educate the immune system for a systemic attack on cancer.

Syncromune competes in the broad cancer immunotherapy space but differentiates itself through its in situ, multi-target combination approach. It faces competition from systemic checkpoint inhibitors, targeted therapies, radiopharmaceuticals, and other cell/gene therapies. Its direct competitors are other intra-tumoral immunotherapy companies, though few combine oncolysis with a multi-target biologic drug in the same procedure.